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Abstract
A mouse leukemia L1210 cell line was selected for resistance to deoxyguanosine. The
deoxyguanosine-resistant cells (dGuo-R) were 126-fold less sensitive to deoxyguanosine than the
wild-type cells. The IC50 values for araC and araG were increased, but only 10–12-fold in the dGuo-
R cells when compared with the wild-type cells. The dGuo-R cell line showed an increased level of
resistance to 2-fluoro-2′-deoxyadenosine and 2-fluoroadenine arabinoside (11–14-fold), but
essentially no increase in resistance to deoxyadenosine or adenine arabinoside. Deoxyribonucleoside
kinase activity was decreased only slightly (19%) when deoxycytidine was utilized as substrate; when
cytosine arabinoside or deoxyguanosine was used as the substrate, the kinase activity in the extracts
from the dGuo-R cells was only 10% of the enzyme activity in the extracts from the wild-type cells.
The determination of the kinetic parameters, Km and Vmax, indicated that there were marked decreases
in the Vmax values for deoxyguanosine and cytosine arabinoside as substrates, but not for
deoxycytidine as substrate; the Km values for deoxycytidine and cytosine arabinoside were increased
in the extracts from the dGuo-R cells. By use of high-performance liquid chromatography, the kinase
activities in the extracts from the wild-type and resistant cells could be resolved. There was the
specific loss of kinase activity toward cytosine arabinoside and deoxyguanosine as substrates. These
data indicate that the dGuo-R cells have decreased levels of a specific deoxyribonucleoside kinase
activity.
Ribonucleotide reductase consists of two nonidentical protein subunits which are both required
for enzymatic activity. One of the subunits contains the tyrosyl free-radical and nonheme iron;
the other subunit contains at least two allosteric binding sites for the nucleoside 5′-triphosphates
which act as positive and negative effectors of enzyme activity. A high affinity site binds ATP
and dATP, while the low affinity site binds ATP, dATP, dGTP, and dTTP (1). Previous studies
(2,3) had shown that resistance of L1210 cells to deoxyadenosine resulted from the loss of
allosteric control by dATP without an effect on ATP activation or dGTP inhibition of CDP
reduction supporting the idea that multiple effector-binding sites are responsible for controlling
ribonucleotide reductase activity.
In continuing studies directed at exploring the nature of the nucleotide-binding sites on the
effector-binding subunit of ribonucleotide reductase, L1210 cells, in culture, were exposed to
increasing concentrations of deoxyguanosine to determine if a deoxyguanosine-resistant cell
line could be selected in which the ribonucleotide reductase activity would be insensitive to
dGTP as a negative inhibitor of CDP, UDP, and GDP reductions.
In the studies to be reported here, we describe the generation of a deoxyguanosine-resistant
(dGuo-R) cell line. This dGuo-R cell line was resistant to araC1 and araG but still sensitive to
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dAdo; kinase activity toward dGuo and araC as substrates was markedly decreased; kinase
activity toward dCyd as substrate was only minimally decreased. These data indicate that the
dGuo-R cell line had decreased levels of a relatively specific deoxyribonucleoside kinase with
preferred substrate specificity toward dGuo, araG, and araC.
EXPERIMENTAL PROCEDURES
Materials
The labeled nucleosides were purchased from commercial suppliers: [3H]deoxycytidine, 25.3
or 27 Ci/mmol, ICN Radiochemicals, Costa Mesa, CA; [3H]cytosine arabinoside, 30 Ci/mmol,
Amersham; and [3H]deoxyguanosine, 4 Ci/mmol, Moravek Biochemicals, Brea, CA. The
unlabeled nucleosides and other biochemicals were purchased from Sigma. 2-FdAdo and 2-
FaraA were gifts from Dr. John A. Montgomery, Southern Research Institute, Birmingham,
AL. EHNA was purchased from Burroughs-Wellcome, Research Triangle Park, NC. 8-
Aminoguanosine was purchased from United States Biochemicals.
The RPMI 1640 culture medium, horse serum, and sodium bicarbonate were purchased from
GIBCO. The wild-type L1210 cell line was originally purchased from the American Type
Culture Collection. The MTS was a gift from Dr. Terence C. Owen, Department of Chemistry,
University of South Florida, Tampa, FL.
Methods
Growth of L1210 Cells—L1210 cells were grown in suspension culture in RPMI 1640
medium supplemented with 10% horse serum, sodium bicarbonate (2 g/liter), and gentamicin
sulfate (50 mg/liter). The cells were grown at 37 °C in a humidified incubator with 5%
CO2/95% air. The dGuo-resistant cell line was generated from the wild-type L1210 cell lines
by the selective pressure of growing the cells in increasing concentrations of dGuo. No
chemical mutagen was used for the selection of this cell line. 8-Aminoguanosine was included
to inhibit purine phosphorylase activity (4), but the concentration was held constant at 25 μM
throughout the selection of the dGuo-R cell line. The wild-type L1210 cells were grown in the
presence of dGuo (120 μM) and 8-aminoguanosine (25 μM)for 24 h. The cells (75 cells/dish)
were plated out on soft agar (Sea-Kem agar, 0.275%, with 20% horse serum). The large colonies
which grew out were “plucked” and regrown in suspension culture. These cells were then
grown in increasing concentrations of dGuo at a constant concentration of 8-aminoguanosine
(25 μM). The cell line which had the highest IC50 value toward dGuo was selected for further
study. The doubling times of the wild-type and dGuo-resistant cells were the same.
Cell Growth Assay—L1210 cell growth was assayed using the method of Cory et al. (5) in
which MTS was substituted for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide. The formazan product of MTS is water-soluble and easily measured at 492 nm in a
96-well plate reader. The 96-well plates were set up with 2,000 cells/well (150 μl) on day 0.
The drugs at various concentrations were added 24 h later in a volume of 50 μl; and 72 h later
the MTS/phenazine methosulfate was added, and the plates were read at 492 nm as described
(5). The 96-well plates were set up with two rows of control cells (no drugs); before the addition
of MTS/phenazine methosulfate, the contents of one row of control cells were removed from
the wells, pooled, and counted on a Coulter counter, Model ZF (Coulter Electronics, Hialeah,
FL). In this way the absorbance of the formazan product of the control cells could be related
1The abbreviations used are: araC, cytosine arabinoside; araG, guanine arabinoside; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; DTT, dithiothrietol; HPLC, high-performance liquid
chromatography; 2-FdAdo, 2-fluoro-2′-deoxyadenosine; 2-FaraA, 2-fluoroadenine arabinoside; MAIQ, 4-methyl-5-aminoisoquinoline
thiosemicarbazone; EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine; dGuo, 2′-deoxyguanosine; dCyd, 2′-deoxycytidine; dAdo, 2′-
deoxyadenosine.
Cory et al. Page 2













to an actual cell count. In a typical experiment the cells in the control wells grew to a
concentration of 200,000–300,000 cells/well. The IC50 values were determined for each drug
in at least three separate experiments. In each experiment, each drug concentration was set up
in three or six separate wells. At least five different concentrations of each drug were used to
determine the IC50. In those studies in which EHNA was used, the EHNA concentration was
kept constant at 5 μM.
Metabolism of 3H-Labeled Nucleosides in Wild-type and dGuo-resistant Cells—
Log-phase wild-type and dGuo-resistant cells were set up in triplicate cultures at 1 × 106 cells/
ml (20 ml) and incubated at 37 °C for 30 min. [3H]Deoxycytidine (27 or 25.3 Ci/mmol, 0.25
μCi/ml), [3H]dGuo (4 Ci/mmol, 0.25 μCi/ml), or [3H]araC (30 Ci/mmol, 0.25 μCi/ml) was
added to the cells, and the incubation was continued for 1 h at 37 °C in the CO2/air incubator.
After 1 h, the cells were collected by centrifugation, washed with cold phosphate-buffered
saline, and recentrifuged. The cell pellet was extracted with 1 ml of 6% perchloric acid, the
homogenate was centrifuged, and the pellet was re-extracted with 0.5 ml of 6% perchloric acid.
The acid-soluble fractions were pooled, and the acid-insoluble pellet was solubilized in 0.25
M NaOH (1 ml). Aliquots of the acid-soluble and acid-insoluble fractions were taken for 3H
determination by liquid scintillation counting. Each experiment was carried out twice, and there
were triplicate flasks per labeled nucleoside in each experiment.
Assay of Deoxyribonucleoside Kinase Activity—Log-phase wild-type and dGuo-
resistant L1210 cells were suspended in 0.05 M HEPES, pH 7.5, containing 1 mM DTT at a
concentration of 3.33 × 108 cells/ml of buffer. The cells were homogenized in a glass vessel
using a motor-driven Teflon pestle. The homogenates were centrifuged for 1 h at 15,000 RPM,
and the supernatant fluids were removed and quick-frozen in small aliquots in a dry-ice acetone
bath. These cell-free extracts were used to assay deoxyribonucleoside kinase activity with
[3H]dCyd, [3H]dGuo, or [3H]araC as the substrate.
The deoxyribonucleoside kinase activities were assayed with the standard conditions of
deoxynucleoside (50 μM, 0.4 μCi), ATP (5 mM), DTT (1.5 mM), magnesium acetate (10 mM),
HEPES buffer, pH 7.5 (0.05 M), and extract (150–200 μg of protein). The reaction mixture had
a final volume of 100 μl. The reaction assays were set up in triplicate; all assays were run at
37 °C. Preliminary experiments showed that product formation was linear for at least 30 min.
The usual assay was run for 20 min. The reactions were stopped by heating for 4 min in a
boiling water bath. Heated controls served as background counts. The samples were centrifuged
in a Microfuge to pellet the protein; aliquots (10 μl) of the supernatant fluids were spotted on
DEAE-cellulose discs. These discs were dried and washed in water (three changes of water).
The discs were placed in scintillation vials and 1 ml of 0.1 M HCl added to each vial to elute
the nucleotide product from the DEAE-cellulose.
For the determination of the kinetic parameters, Km and Vmax, the substrate concentrations
were varied with a constant level of tritiated substrate. The amount of cell-free extract for the
dGuo-resistant cells was doubled in those assays. The Km and Vmax values were determined
by linear regression analysis of the Lineweaver-Burk plots. The nature of the inhibition and
the Ki values were determined from Dixon plots (6).
Separation of Deoxyribonucleoside Kinase Activities by HPLC—Cell-free extracts
(12 mg of protein/ml) were passed through a 0.22-μm filter. An aliquot (0.3 ml) was loaded
onto the Mono Q column (Pharmacia LKB Biotechnology Inc.), and a gradient was run to elute
the protein fractions. The gradient was run in 0.05 M Tris-HCl, pH 7.6, containing 1 mM DTT
starting with an initial concentration of 0.09 M KCl to a final concentration of 0.50 M KCl. This
gradient was run over 45 min. Fractions (1 ml) were collected, immediately put on ice, and
then used for the assay of deoxyribonucleoside kinase activities. The assay mix consisted
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of: 3H-labeled substrate, 0.2 μCi, 10 μM; ATP, 5 mM; magnesium acetate, 2 mM; DTT, 1.5 mM;
HEPES, pH 7.5, 0.05 M; and an aliquot (25 μl) of the protein fraction off the HPLC column.
The final reaction volume was 50 μl. The assays for each substrate were set up in duplicate.
The reactions were run for 1 h at 37 °C. The reactions were stopped by heating for 4 min in a
boiling water bath. Aliquots (20 μl) were spotted on DEAE-cellulose discs and washed as
described above.
Protein Determination—The protein concentrations in the cell-free extracts were
determined by the method of Lowry et al. (7) using the bovine plasma γ-globulin (Bio-Rad)
as the standard.
RESULTS
Comparison of the Effects of Various Antitumor Agents on the Growth of Wild-type and
dGuo-R L1210 Cells
The effects of a selected group of antitumor agents on the growth of wild-type and dGuo-R
L1210 cell lines were studied. The data for the IC50 values of these compounds are compared
in Table I. The L1210 cell line selected for resistance to dGuo showed a 126-fold increase in
the IC50 toward dGuo. This dGuo-R cell line was also resistant to araC and araG, but the level
of resistance was increased only 10–12-fold. These data suggested that the resistance was due
to the loss of deoxyribonucleoside kinase activity. For comparative purposes, studies with other
compounds were carried out. The dGuo-R cell line showed only a modest decrease in sensitivity
to dAdo/EHNA (3-fold) or araA/EHNA (2-fold). On the other hand, the dGuo-R cell line
showed an 11-fold decrease in sensitivity to 2-FdAdo/EHNA and at least a 14-fold decrease
in sensitivity to 2-FaraA. The ribonucleotide reductase inhibitors, hydroxyurea and MAIQ,
which do not have to be activated through a kinase-mediated reaction, were also compared in
these two cell lines. The dGuo-R cell line showed a 2-fold decrease in sensitivity toward
hydroxyurea but essentially no change in sensitivity toward MAIQ.
Uptake and Metabolism of [3H]Deoxycytidine, [3H]Deoxyguanosine, and [3H]Cytosine
Arabinoside in Wild-type and dGuo-R L1210 Cells
The uptake and incorporation of tritiated dCyd, dGuo, or araC into the acid-soluble and acid-
insoluble fractions of wild-type and dGuo-R L1210 cells were determined. As seen from the
data in Table II, the dGuo-R cells showed a marked decrease in the total uptake of the labeled
nucleosides into the cell as measured in the acid-soluble and acid-insoluble fractions. The
dGuo-R cell line metabolized [3H]dGuo to only 9% of the wild-type cells; the uptake and
metabolism of [3H]dCyd and [3H]araC were decreased to 27 and 21%, respectively, in the
dGuo-R cells.
Deoxyribonucleoside Kinase Activity in Cell-free Extracts from Wild-type and dGuo-R Cells
Cell-free extracts were prepared from log-phase wild-type and dGuo-R cells. The
deoxyribonucleoside kinase activity in these extracts was assayed using [3H]dCyd, [3H]dGuo,
or [3H]araC as substrate at substrate concentrations of 50 μM. As seen from the data in Table
III, the dCyd kinase activity was only slightly decreased in the drug-resistant cell lines at this
substrate concentration. On the other hand, the kinase activity or activities which
phosphorylated dGuo and araC was/were reduced to approximately 10% of the wild-type level.
Studies were then carried out to determine the kinetic parameters Km and Vmax from
Lineweaver-Burk plots with dCyd, dGuo, or araC as substrate using the cell-free extracts from
the wild-type and dGuo-R cell lines. These data are summarized in Table IV. With dCyd as
substrate, the Vmax was 1.37-fold larger in extracts from the dGuo-R cells than in the extracts
from the wild-type cells, while the Km for dCyd was 8-fold larger for the kinase activity from
the dGuo-R cells. In the extracts from the dGuo-R cells, the Vmax with dGuo as substrate was
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only 4% of that seen in the extracts from the wild-type cells; the Km for dGuo was decreased
approximately 4-fold with the kinase in the dGuo-R cells. The Vmax with araC as substrate was
decreased in the extracts from the dGuo-R cells to 35% of the value obtained in the extracts
from the wild-type cells. In addition, this decrease in Vmax was accompanied by a 15-fold
increase in the Km for araC for the kinase in the dGuo-R cells.
The effect of araC on dCyd kinase activity was determined as well as the effect of dCyd on
araC kinase activity. Using Dixon plots, it was found that araC was a competitive inhibitor of
the phosphorylation of dCyd with a Ki of 390 μM. Conversely, dCyd was a competitive inhibitor
of araC phosphorylation with a Ki of 0.3 μM. However, dCyd and araC at concentrations as high
as 1500 and 2500 μM, respectively, did not inhibit the phosphorylation of dGuo.
Separation of Deoxyribonucleoside Kinase Activities in Extracts from Wild-type and dGuo-
R Cells by HPLC
Cell-free extracts prepared from the wild-type and dGuo-R L1210 cells were separated on a
Mono Q column by HPLC. Aliquots of the fractions were assayed for kinase activity utilizing
[3H] dCyd, [3H]dGuo, and [3H]araC as substrates. These data are shown in Fig. 1, A and B.
Fig. 1A shows the kinase activities in the extracts from the wild-type cells in the fractions
obtained from the HPLC column; Fig. 1B shows the kinase activities in the extracts from the
dGuo-R L1210 cells in the fractions from HPLC column. As seen in Fig. 1A, the peak of dCyd
kinase activity occurred at fraction 31, with the peak of dGuo and araC kinase activities being
at tube 30; there was a small shoulder of dCyd and araC kinase activities. Deoxyguanosine
kinase activity showed two distinct peaks. As seen in Fig. 1B, there was a marked decrease in
kinase activities toward dGuo and araC as substrates, with the major loss of activities
corresponding to the larger peak of activity (tube 30). The kinase activities toward dCyd, dGuo,
and araC were resolved into two peaks in the extracts from the dGuo-R cells due to the decrease
of the main peak of activities. Fig. 1C shows the UV profile of the protein eluting from the the
HPLC column. The extracts from the wild-type and dGuo-resistant cells gave identical protein
elution profiles. The peak of enzyme activities eluting from the column did not correlate with
the peak of protein at tube 25.
DISCUSSION
As a result of efforts to generate a deoxyguanosine-resistant cell line which had an altered
dGTP binding site on ribonucleotide reductase, we isolated an L1210 cell line which was highly
resistant to dGuo, but this was due to the rather selective loss of a deoxyribonucleoside kinase.
This deoxyribonucleoside kinase-deficient cell line has some interesting and selective cross-
resistant patterns.
Using the IC50 values, the sensitivity of the dGuo-R cell line to a series of nucleosides and
nucleoside analogs was compared with the wild-type L1210 cell line. The dGuo-R L1210 cell
line was highly resistant to dGuo (126-fold). This cell line also showed modest resistance to
araC and araG (10–12-fold). Shewach et al. (8) reported on a MOLT-4 T-lymphoblast cell line
which was highly resistant to araG (600-fold) with a relatively modest 36-fold increase in
resistance to dGuo and only a 4-fold increase in resistance to araC. Whether the difference in
the levels of araC and araG resistance relative to the level of resistance to dGuo in the dGuo-
R L1210 cells is due only to the loss of a relatively specific deoxyribonucleoside kinase activity
or is also due to the altered ability of the mutant L1210 cell line to maintain araGTP, araCTP,
or dGTP levels is not known. Clearly, the level of incorporation of [3H]dGTP into DNA was
decreased by 91% in the dGuo-R cells (Table II). The decreased level of [3H]dCyd
incorporation into DNA in the dGuo-R cells compared to the wild-type cells (27% of the wild-
type cells) in spite of the relatively small decrease in dCyd kinase activity may be related to
the 8-fold increase in Km (Table IV) and the fact that in the cell-labeling studies, the substrate
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was not at a saturating concentration. Bhalla et al. (9) have shown that a highly araC-resistant
HL-60 cell line which had only 1.2% of the dCyd kinase activity of the wild-type HL-60 cell
line was as sensitive to dAdo or dGuo as the wild-type HL-60 cells. Interestingly, while the
dGuo-R L1210 cell line showed only a 2–3-fold increase in IC50 toward dAdo or araA, there
was a marked increase in the level of resistance of the dGuo-R cells to the fluorinated
derivatives (2-FdAdo and 2-FaraA). These data indicate that different kinases may be utilized
by the cells in activating dAdo versus 2-FdAdo and araA versus 2-FaraA. Krenitsky et al.
(10) had previously shown that the dCyd kinase from calf thymus had much higher substrate
efficiencies (Vmax/Km) for 2-FaraA and 2-FdAdo than for the non-fluorinated compounds, araA
and dAdo. Hershfield et al. (11) and Verhoef et al. (12) have shown that dAdo is phosphorylated
by both dCyd kinase and Ado kinase. Furthermore, Dow et al. (13) have shown that a CCRF-
CEM cell line deficient in dCyd kinase activity was highly resistant to 2-FaraA but not araA.
Our data, in terms of the specificity of resistance to 2-FdAdo and 2-FaraA, can be explained
by these observations of Krenitsky et al. (10), Hershfield et al. (11), and Dow et al. (13). The
dGuo-resistant cells did not show cross-resistance to compounds such as hydroxyurea or
MAIQ, inhibitors of ribonucleotide reductase, that do not have to be activated via a kinase-
mediated reaction. This would suggest that the nature of the alteration in the mutant cells was
relatively specific. When the deoxyribonucleoside kinase activities were compared in cell-free
extracts prepared from the wild-type and dGuo-R cells under a standard assay condition of
substrate at 50 μM, it was found that dCyd kinase activity in the dGuo-R cells was 81% of the
wild-type cells. However, kinase activity toward dGuo and araC as substrates was selectively
reduced to 10% of the wild-type levels. In this regard, Richel et al. (14) isolated a rat leukemia
cell line which was resistant to araC. Deoxyribonucleoside kinase activity toward dCyd as
substrate was the same in both the wild-type and the araC-resistant cell line. With araC as the
substrate, there was no kinase activity in the resistant cell line (14). In our experiments the
levels of enzyme activity measured in the cell-free extracts (Table III) utilizing a substrate
concentration of 50 μM, agree extremely well with the values calculated using the Vmax and
Km values determined (Table IV) in the Michaelis-Menten expression [υ = Vmax(S)/Km + (S)]
taking into account the changes in Vmax and Km observed in the dGuo-resistant cell line. The
Km values observed in this study agree well with the published values obtained for murine
systems. Habteyesus et al. (21) reported a Km (dCyd) of 1.8 μM, while Myers and Kreis (15)
reported a Km (dCyd) of 9.3 μM; in our studies we obtained a Km (dCyd) of 5 μM. For araC, a
Km (araC) of 30 μM was reported (21), while we obtained a Km (araC) of 16 μM. Neither
Habteyesus et al. (21) nor Myers and Kreis (15) reported a Km for deoxyguanosine as substrate.
The relative Vmax values for dCyd and araC as substrates were in excellent agreement; i.e. the
Vmax for araC was larger than the Vmax for dCyd as reported by Habteyesus et al. (21) and this
study (Table IV). The resolution of the kinase activities on the Mono Q column suggests that
there are multiple kinase activities (Fig. 1, A and B). Other investigators have reported on the
separation of the kinase activities. Meyers and Kreis (15) and Lewis and Link (16) have shown
that dGuo kinase activity could be separated from dCyd kinase activity. In the wild-type L1210
cells, there is a major peak of kinase activity which is capable of phosphorylating dCyd, dGuo,
and araC. In the dGuo-R cells there was a marked decrease in the kinase activity with dGuo
and araC as substrates but only a small decrease in the kinase activity which phosphorylates
dCyd. In the extract from the dGuo-R cells, there was a clear resolution of the dCyd and araC
kinase activities into two peaks. These data would suggest that there was the specific loss of a
kinase with preferred substrate specificity for dGuo and araC. Furthermore, the ratio of Vmax
values for dGuo and araC as substrates was not the same in the extracts from the wild-type and
dGuo-R cell lines. In the wild-type cells the ratio was 2.94, while the ratio was 0.35 in the
dGuo-R cells, indicating a greater loss of the deoxyguanosine kinase activity.
An interesting kinetic feature of dCyd kinase has been observed in the study of dCyd kinase
from several different types of cells (17,18). For example: the Km for a substrate such as dCyd
was not approximately equivalent to its Ki as a competitive inhibitor of a substrate such as
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dGuo or dAdo; the Ki for araC as a competitive inhibitor varied 100-fold depending on whether
the substrate was dCyd or dGuo (18); and the Km for araC was 30,000 times greater than its
Ki with respect to dCyd as substrate (17). Our results are in agreement with these observations.
The second substrate acted as a competitive inhibitor, but the Ki values did not approximate
the Km values. The Ki for araC as a competitive inhibitor of dCyd was 390 μM compared to a
Km of 15 μM for araC as a substrate; dCyd as a substrate had a Km of 5 μM and a Ki of 0.3 μM
with respect to araC as substrate. AraC and dCyd, at concentrations as high as 2.5 and 1.5
mM, respectively, did not inhibit the phosphorylation of dGuo. These kinds of results have been
interpreted as being due to allosteric effects which result in multiple forms of the enzyme
(18). Taken together, the kinetic data and the resolution of the deoxyribonucleoside kinase
activities on the Mono Q column are consistent with the possibility that the L1210 cells have
a deoxyribonucleoside kinase with a substrate preference for deoxyguanosine over the other
deoxyribonucleosides and arabinonucleosides.
The molecular basis for the loss of this deoxyribonucleoside kinase activity in the L1210 cell
line is not known. The recent results of Clottiner et al. (19) using human cell lines have shown
that the level of the mRNA for dCyd kinase was decreased in cell lines resistant to araC.
Detailed analysis of two human cell lines that had decreased deoxyribonucleoside kinase
activities toward dCyd, dAdo, and dGuo showed that the molecular bases for the decreased dN
kinase activities in these two cell lines were multiple and different (20). One cell line (ara-
C-8D) had two mutations: (a) one allele had a deletion of exon 5 (nucleotides 710–825) of the
dCK gene; and (b) the second allele had a G → A transition at nucleotide 242 (kinase ATP
binding domain). The second cell line (ddC50) had a point mutation resulting in a A → G
transition at nucleotide 626 with the other allele not being expressed. In both cell lines the dCK
activity was markedly reduced, but to a much larger extent in the ara-C-8D cell lines. It is
possible that the changes observed in the dN kinase activities in the dGuo-R cell line is the
result of two different mutated alleles or the selective silencing of one of the kinase alleles.
Habteyesus et al. (21) have shown that the purified dCyd kinases from human and mouse
tissues have different substrate specificity properties which make extrapolation from the studies
in human cells to the mouse cells not necessarily appropriate.
Clearly, one level of resistance of the dGuo-R cells resides in the loss of a relatively specific
deoxyribonucleoside kinase activity. There may be, in addition, other factors at the cellular
level such as the steady-state concentrations of the active inhibitory species (dGTP, araCTP,
araGTP) which are maintained and which influence the cross-resistance patterns in the dGuo-
R cells. Whether the decreased kinase activity is due, at the molecular level, to decreased
mRNA levels or to a mutated mRNA which codes for a kinase with altered enzyme activities
or decreased half-life remains to be determined. The dGuo-R cell line will be useful in studying
the role of specific deoxyribonucleoside kinases in the activation of nucleoside analogs as
antitumor agents.
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Fig. 1. Deoxyribonucleoside kinase activities in fractions separated by HPLC
The dCyd kinase (•), araC kinase (○), and dGuo kinase (▪) activities were determined in the
fractions off the HPLC column. Equal amounts of extract protein from the wild-type and dGuo-
R cells were put on the column. A shows the kinase activities in the extract from the wild-type
cells; B shows the kinase activities in the extract from the dGuo-R cells; C shows the UV profile
of the protein eluting from the column (the extracts from the wild-type and dGuo-R cells gave
the same profile). Note that the y axis for A and B is a log plot. Extracts from the wild-type
cells were run over the HPLC column in four different experiments; extracts from the dGuo-
R cells were run over the HPLC column in two separate experiments. For dCyd, dGuo, and
araC as substrates, 10,000 dpm of product on the filter paper were equivalent to 0.012, 0.027,
and 0.013 nmol/h.
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Table I




Compound WT dGuo-R Ratio dGuo-R/WT
μM
dGuo/8AGuo 11.8 ± 1.3 1520 ± 470 126
araG 30.8 ± 3.2 384 ± 62 12
araC 60.0 ± 6.8 595 ± 68 10
dAdo/EHNA 15.0 ± 2.4 42 ± 2.6 3
2-FdAdo/EHNA 2.9 ± 0.05 32 ± 1 11
araA/EHNA 1.8 ± 0.17 4.1 ± 1.2 2
2-FaraA 6.9 ± 0.88 >100 >14
Hydroxyurea 76.7 ± 14.4 138 ± 48 2
MAIQ 2.3 ± 0.53 2.7 ± 0.4 1
a
 The IC50 values are the average of at least three separate determinations.
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Table II
Uptake and metabolism of [3H]deoxycytidine, [3H]deoxyguanosine, and [3H]cytosine arabinoside in wild-type
and deoxyguanosine-resistant L1210 cells
Labeled nucleoside Fraction Wild-type dGuo-R
cpm/106 cellsa
[3H]dCyd Acid-soluble 4,150 1,800 (0.43)b
Acid-insoluble 9,950 2,090 (0.21)
Total 14,100 3,900 (0.27)
[3H]dGuo Acid-soluble 20,330 2,010 (0.10)
Acid-insoluble 41,390 3,870 (0.09)
Total 61,720 5,880 (0.09)
[3H]araC Acid-soluble 4,070 800 (0.20)
Acid-insoluble 350 50 (0.21)
Total 4,430 850 (0.21)
a
 Average of duplicate experiments in which there were three flasks for each cell type set up in each experiment. There was less than 10% difference
between the two separate experiments.
b
 Ratio of the labeled fraction in the dGuo-R cells versus the wild-type cells.
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Table III




[3H]dCyd 0.106 0.086 (0.81)b
[3H]dGuo 0.220 0.024 (0.11)
[3H]araC 0.153 0.016 (0.10)
a
dN kinase activity was measured utilizing the respective substrate at 50 μM final concentration.
b
Ratio of dN kinase activity in the dGuo-R versus the wild-type L1210 cells.
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Table IV
Kinetic parameters for deoxynucleoside kinase activities in wild-type and deoxyguanosine-resistant cells
Average of two separate determinations of Km and Vmax; in each experiment, each substrate concentration was
set up in triplicate and at least five different substrate concentrations were used.
Cell type S Km Vmax
μM nmol/min/mg protein
Wild-type DCyd 5 0.159
DGuo 144 0.763
AraC 16 0.259
dGuo-R Dcyd 40 0.222
DGuo 39 0.032
AraC 250 0.092
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